That’s what researchers are cautiously heralding after trial results showed a new drug could slow cognitive decline by more than a 3rd. According to US drugmaker Eli Lilly, out of the 1,734 early-stage Alzheimer’s patients who took part in the trial, donanemab slowed the condition’s progress by 35% compared with those who were given a placebo. It’s the 2nd drug to succeed in trials after lecanemab was proven to work last year. Both drugs work to clear out proteins that build up in the brain that are thought to cause Alzheimer’s, which is the most common form of dementia. But researchers warn donanemab still poses some risks, with up to a 3rd of patients experiencing mild brain swelling and 3 dying from severe side effects. Eli Lilly said it would start the approval process with America’s Food and Drug Administration next month, followed by regulators in other countries.